Literature DB >> 4896078

Desipramine in treatment of Parkinson's disease. A placebo-controlled study.

L Laitinen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4896078     DOI： 10.1111/j.1600-0404.1969.tb01224.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


× No keyword cloud information.
  11 in total

1.  Depression in Parkinson's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Effects of desipramine on neuronal responses to dopamine, noradrenaline, 5-hydroxytryptamine and acetylcholine in the caudate nucleus of the rat.

Authors:  P Bevan; C M Bradshaw; E Szabadi
Journal:  Br J Pharmacol       Date:  1975-07       Impact factor: 8.739

Review 3.  Depression in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Robert A Hauser
Journal:  Curr Psychiatry Rep       Date:  2002-02       Impact factor: 5.285

Review 4.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 5.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 6.  Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Authors:  Daniel Weintraub; Knashawn H Morales; Paul J Moberg; Warren B Bilker; Catherine Balderston; John E Duda; Ira R Katz; Matthew B Stern
Journal:  Mov Disord       Date:  2005-09       Impact factor: 10.338

7.  The neuropathological basis for depression in Parkinson's disease.

Authors:  Pasquale G Frisina; Vahram Haroutunian; Leslie S Libow
Journal:  Parkinsonism Relat Disord       Date:  2008-06-20       Impact factor: 4.891

Review 8.  Treatment of depression in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

9.  Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals.

Authors:  A Lupp; K I Bär; C H Lücking; T J Feuerstein
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Synergistic anticataleptic effect of imipramine and nicotine in a rotenone-induced rat model.

Authors:  Ilya D Ionov; Irina I Pushinskaya; Nicholas P Gorev; Larissa A Shpilevaya
Journal:  Psychopharmacology (Berl)       Date:  2019-05-08       Impact factor: 4.415
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.